TIRZEPATIDE, 10 mg

TIRZEPATIDE, 10 mg
CA$90.00

Tirzepatide is a synthetic dual‑agonist peptide studied for its simultaneous activation of GLP‑1 and GIP receptors—two key pathways involved in blood‑sugar regulation, insulin sensitivity, and fat‑metabolism control. Research interest has grown rapidly due to its strong metabolic effects, including significant reductions in body weight and improvements in glucose handling.

 

Key Benefits of Tirzepatide

As of March 2026, Tirzepatide is FDA-approved under two main brand names: Mounjaro (for Type 2 Diabetes) and Zepbound (for Weight Management and Obstructive Sleep Apnea).

 

  • Superior Weight Loss: In clinical trials (SURMOUNT-1), participants without diabetes lost an average of 20.9% to 22.5% of their body weight over 72 weeks. This is nearly double the average weight loss seen with first-generation GLP-1s.

     

  • Exceptional Glycemic Control: For those with Type 2 Diabetes, it has shown the ability to reduce HbA1C by up to 2.3%, often helping patients reach "non-diabetic" blood sugar levels more effectively than insulin or other oral medications.

     

  • Treatment for Sleep Apnea: In late 2024/early 2025, Tirzepatide became the first medication FDA-approved to treat Obstructive Sleep Apnea (OSA). It reduces the frequency of breathing interruptions by an average of over 60% at the highest dose.

     

  • Cardiovascular & Lipid Health: It significantly lowers "bad" cholesterol (LDL) and triglycerides while reducing systolic blood pressure. 2026 data also highlights its ability to reduce the risk of major adverse cardiovascular events (MACE).

     

  • Liver Fat Reduction: Like its cousin Retatrutide, Tirzepatide is a potent tool for treating MASH (Fatty Liver), with studies showing significant reductions in liver fat and inflammation.

     

  • Elimination of "Food Noise": Perhaps the most noted benefit by users is the total suppression of intrusive thoughts about food, allowing for a more intuitive relationship with eating.